Abstract
ABSTRACT
Background and Aims
Lipid dysregulation plays a crucial role in psoriasis pathogenesis and its cardiometabolic comorbidities. Novel anthropometric indices such as Body Roundness Index (BRI), Lipid Accumulation Product (LAP), and Triglyceride‐Glucose (TyG) index have been proposed to better reflect underlying metabolic dysfunction and may be associated with psoriasis risk, severity, and related complications. This systematic review evaluates the current evidence on the associations of BRI, LAP, and the TyG index with psoriasis and related clinical outcomes.
Methods
A comprehensive literature search was conducted from inception up to September 2025. Observational studies examining the relationship between BRI, LAP, or TyG index and psoriasis or its clinical outcomes were included. Data synthesis comprised qualitative and descriptive statistical analyses.
Results
Fifteen studies comprising 65,130 participants from diverse countries met the inclusion criteria. Higher LAP was consistently associated with increased psoriasis risk but showed weak or no correlation with disease severity (PASI). All BRI studies, primarily using US National Health and Nutrition Examination Survey data, demonstrated a positive association between BRI and psoriasis risk, with modest predictive ability (AUC 0.56–0.58). TyG index was linked to adverse metabolic and cardiovascular outcomes, fatty liver disease, and all‐cause mortality in psoriasis patients, although correlations with PASI were generally non‐significant.
Conclusions
BRI, LAP, and TyG index are consistently associated with psoriasis risk and related metabolic and cardiovascular complications, highlighting their potential utility for early risk stratification and holistic management of psoriasis patients. Further prospective studies are warranted to clarify their predictive value for disease severity and long‐term outcomes.